Original Source
AcuityMD Raises $80M to Bolster AI in Medtech Industry
AcuityMD Secures $80 Million Investment for AI-Powered Medtech
AcuityMD has successfully raised $80 million to enhance its artificial intelligence (AI) platform, which aims to improve various operational aspects for medtech companies. This latest funding round brings the company's valuation close to $1 billion. With a total of $160 million raised to date, AcuityMD plans to deploy these funds to establish agentic AI systems for commercial personas, including sales representatives, leadership, and marketing teams. The company, founded in 2019, previously secured Series A funding in 2022 and a $45 million Series B round in 2024.
Accelerating Medtech Adoption and Expanding AcuityAI System
Beyond establishing AI systems, AcuityMD intends to utilize the new capital to advance its broader mission: accelerating the adoption of medical technology across the full product lifecycle. Its core system, AcuityAI, is currently in an open beta phase, designed to enable sales reps to focus more time with the right physicians, equipped with the necessary context to secure more business. Mike Monovoukas, CEO and co-founder of AcuityMD, stated, “AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made.”
*Source: Fierce Biotech (2026-04-22)*
